enVVeno Medical (NASDAQ:NVNO) Announces Earnings Results, Misses Expectations By $3.02 EPS

enVVeno Medical (NASDAQ:NVNO) posted its quarterly earnings results on Thursday. The company reported ($6.29) EPS for the quarter, missing the consensus estimate of ($3.27) by ($3.02), FiscalAI reports.

enVVeno Medical Trading Down 3.9%

enVVeno Medical stock traded down $0.28 during trading hours on Friday, hitting $6.75. 9,085 shares of the stock traded hands, compared to its average volume of 20,391. enVVeno Medical has a one year low of $6.52 and a one year high of $25.90. The firm’s 50-day moving average price is $9.04 and its two-hundred day moving average price is $10.35. The company has a market cap of $4.69 million, a PE ratio of -0.35 and a beta of 1.29.

Analysts Set New Price Targets

Several equities analysts have recently commented on NVNO shares. Wall Street Zen raised shares of enVVeno Medical to a “hold” rating in a research note on Saturday, October 24th. Zacks Research raised enVVeno Medical to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings restated a “sell (e+)” rating on shares of enVVeno Medical in a report on Friday, September 25th. Finally, LADENBURG THALM/SH SH raised enVVeno Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, enVVeno Medical currently has a consensus rating of “Hold”.

enVVeno Medical Company Profile

enVVeno Medical Corporation (NASDAQ:NVNO) is a late-stage medical device company focused on developing bioprosthetic, or tissue-based, treatments for venous disease. Its primary focus is chronic venous insufficiency, a condition in which damaged or absent valves allow blood to flow backward in the veins and can cause swelling, pain, skin changes and ulcers.

The company’s lead product is the VenoValve, a surgically implanted bioprosthetic valve designed to restore one-way blood flow in the deep veins of the leg.